Degos disease is a rare and often fatal vascular disorder in which small- and medium-sized blood vessels become progressively blocked, causing distinctive skin lesions and, in the majority of cases, damage to the gut, brain, or both. Also known as malignant atrophic papulosis or Köhlmeier-Degos disease, it affects fewer than a few hundred documented patients worldwide. A systematic review of published cases found that roughly two-thirds of patients develop the systemic, malignant form, which carries a median survival of just over two years from the time skin lesions first appear.1PubMed Central. Clinical and laboratory prognosticators of atrophic papulosis (Degos disease): a systematic review The remaining third seem confined to skin-only disease, but even that label carries an asterisk.
The Signature Skin Lesions
The hallmark of Degos disease is a distinctive papule that evolves over days to weeks. It begins as a small, pinkish-red bump, usually a few millimeters across, then develops a porcelain-white, atrophic center surrounded by a rim of redness. The lesions tend to cluster on the trunk and upper extremities, though they can appear almost anywhere on the body. Their appearance is unusual enough that an experienced dermatologist can often suspect the diagnosis on sight, but a skin punch biopsy confirms it.2PubMed Central. Degos disease: a case report and review of the literature
Under the microscope, the biopsy typically shows a wedge-shaped zone of tissue death in the upper layer of the dermis, with thinning of the overlying skin. The small blood vessels in the area show clotting within their walls and a particular kind of structural breakdown called fibrinoid necrosis, where the vessel wall itself starts to disintegrate.3PubMed. Degos’ disease This combination of features, a porcelain-white scar over dying dermis with clotted vessels, is the microscopic fingerprint of Degos disease. New lesions can keep appearing for months or years, sometimes numbering in the dozens. On their own, the skin lesions are painless and not life-threatening. The danger lies in what happens when the same vascular process begins inside the body.
When the Disease Reaches the Gut and Brain
Systemic involvement can develop months or years after the first skin lesions appear, making the early period of the disease deceptively calm. The gastrointestinal tract and the central nervous system are the two organ systems hit most often.4PubMed Central. Nervous system involvement in Degos disease. In the gut, the same vascular blockages that create the skin’s white scars cause small infarctions, patches of tissue death along the intestinal wall. These infarctions can weaken the wall enough to perforate it.
A narrative review of 65 published cases found that about half had gastrointestinal perforation, and among those with perforation, half had more than one hole in the bowel at the time they were first examined surgically. Nearly three-quarters of those perforations occurred in the small intestine.5PubMed Central. Kohlmeier–Degos disease: a narrative review Bowel perforation leads to peritonitis, an infection of the abdominal cavity, which remains the single most common cause of death in Degos disease.6PubMed Central. A fatal case of Degos’ disease which presented with recurrent intestinal perforation Of patients who experienced perforation in that same review, only five were alive at the time their cases were published.7PubMed Central. Kohlmeier–Degos disease: a narrative review
Neurological complications are the second major threat. Vascular occlusion in cerebral arteries can cause stroke, and similar blockages in smaller vessels can trigger inflammation of the brain’s lining, spinal cord inflammation, or nerve-root damage. Some patients develop a combination of these problems.8PubMed Central. Malignant atrophic papulosis (Köhlmeier-Degos disease) – a review The neurological decline can be rapid or slow and stuttering, making it hard to predict who will deteriorate quickly.
What Drives the Vascular Damage
The exact cause of Degos disease remains incompletely understood, but research over the past two decades has converged on two interacting mechanisms: overactive interferon signaling and complement-driven injury to the cells lining blood vessels.
Work examining tissue from affected skin, gut, and brain found heavy deposits of a complement fragment called C5b-9, the so-called membrane attack complex, on blood vessel walls. Alongside this, researchers identified a strong interferon-alpha signature, suggesting that a runaway immune signal was driving the vessel damage from two directions at once: the complement system was physically punching holes in vessel-lining cells while interferon signaling kept the inflammatory fire burning.9PubMed. Degos disease: a C5b-9/interferon-α-mediated endotheliopathy syndrome Autopsy findings in another patient confirmed widespread C5b-9 deposits in blood vessels of the skin and throughout the gastrointestinal tract, from the esophagus to the large intestine.10PubMed. A case of Degos disease: demonstration of C5b-9-mediated vascular injury
More recent single-cell analysis has sharpened the picture further. Sequencing of immune cells from the skin, blood, and spinal fluid of Degos patients revealed intense activation of both type I and type II interferon programs. Compared with systemic lupus erythematosus, which also features interferon overactivity, Degos disease showed a stronger bias toward interferon-gamma signaling, suggesting it is a distinct interferonopathy rather than a subset of lupus.11PubMed Central. Single-cell profiling reveals interferon-driven inflammation and cellular immunity in Köhlmeier-Degos disease And there is a clinical clue that interferon sits near the heart of the problem: cases of Degos-like disease have been reported in patients treated with tumor necrosis factor (TNF) inhibitors, drugs that can inadvertently boost interferon-alpha levels. Those iatrogenic cases reinforce the idea that excessive type I interferon, combined with complement attack on endothelial cells, underlies the vessel damage.12PubMed Central. Tumor necrosis factor ALPHA Inhibitor Associated Köhlmeier-Degos Disease as a Novel Iatrogenic Paradigm That Underscores Excessive Type I Interferon in Its Pathogenesis
Some patients also show signs of a clotting tendency layered on top of the vessel injury. Elevated antibodies against cardiolipin and beta-2 glycoprotein, the same markers seen in antiphospholipid syndrome, have been measured in Degos patients’ blood, along with reduced levels of the vessel-growth factor VEGF.13PubMed. Inflammation and thrombo-occlusive vessel signalling in benign atrophic papulosis (Köhlmeier-Degos disease) At least one fatal case occurred in a patient who also carried the factor V Leiden mutation, a common inherited predisposition to blood clots, yet even aggressive anticoagulant and antiplatelet therapy failed to prevent systemic spread.14Acta Dermato-Venereologica. A fatal case of malignant atrophic papulosis (Degos’ disease) in a man with factor V Leinden mutation and lupus anticoagulant That outcome suggests the clotting component may be secondary to the underlying vessel-wall destruction rather than the primary driver.
Is Degos Disease a Single Disease or a Common Endpoint?
One persistent debate in the literature is whether Degos disease is truly its own entity or whether the characteristic skin lesions represent a final common pathway that several different vascular problems can converge on. A series of patients published in the Journal of the American Academy of Dermatology included one with classic Degos disease, two who had the right skin and biopsy findings but also carried laboratory markers of lupus, and a fourth who had dermatomyositis with Degos-like lesions. Because the clinical and microscopic features overlapped so heavily, the authors argued that Degos disease may be less of a stand-alone diagnosis and more of a recognizable pattern that various vascular insults can produce.15PubMed. Is Degos’ disease a clinical and histological end point rather than a specific disease?
This matters for patients because Degos-like lesions that arise in the context of an underlying autoimmune disease behave differently from the standalone form. In the systematic review of 105 patients, those whose Degos-pattern lesions were secondary to a connective-tissue disease like lupus were far less likely to develop the malignant systemic form.16PubMed Central. Clinical and laboratory prognosticators of atrophic papulosis (Degos disease): a systematic review In other words, finding Degos-like papules on someone already diagnosed with lupus is a less ominous sign than finding them on someone with no known autoimmune condition. The distinction has practical implications: treating the underlying autoimmune disease may be enough in those cases, while primary Degos disease requires more aggressive surveillance and, potentially, targeted therapy.
Predicting Systemic Spread
One of the cruelest features of Degos disease is the uncertainty it imposes. A person can live with skin-only lesions for years before internal involvement declares itself. A large systematic review found that systemic disease developed in some patients as late as 28 years after the first skin lesion appeared, making the label “benign cutaneous Degos” less reassuring than it sounds.17PubMed. Clinical manifestations and treatment outcomes in degos disease: a systematic review No one with skin-only disease can truly be declared safe.
Researchers have looked for laboratory markers that might flag the transition from skin-only to systemic disease before perforation or stroke strikes. The most promising signal so far is simple: elevated inflammatory markers. In the 105-patient systematic review, elevations in either erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), two common blood tests for inflammation, were associated with systemic involvement.18PubMed Central. Clinical and laboratory prognosticators of atrophic papulosis (Degos disease): a systematic review These are not highly specific markers; they rise in all sorts of inflammatory conditions. But in a patient already diagnosed with Degos, persistently rising inflammatory markers should prompt closer surveillance of the gut and nervous system.
Beyond blood tests, repeated skin biopsies looking for C5b-9 deposition and the degree of fibrosing arterial changes may offer some clues about disease activity, but no validated staging system exists. Given how rare the disease is, generating enough data for a reliable prognostic model is a challenge that will take years of multi-center collaboration.
Treatment Approaches
No treatment for Degos disease has been tested in a randomized trial, and given the rarity of the condition, one is unlikely. Everything known about therapy comes from individual case reports and small case series. Still, several approaches have emerged that match the disease’s known mechanisms.
The clearest mechanistic target is the complement system. Eculizumab, a drug that blocks complement component C5 and is used for other complement-mediated diseases, was given to one patient as an emergency measure. After rapid initial improvement, the patient continued biweekly infusions for four years. Biopsies taken during treatment showed that active clotting within blood vessels had stopped and C5b-9 deposits were no longer detectable in tissue after about a year. However, the drug did not eliminate the underlying interferon signature or the fibrotic narrowing of arteries, and the patient continued to have abdominal symptoms.19PubMed Central. The effects of Eculizumab on the pathology of malignant atrophic papulosis Eculizumab addressed one arm of the disease, complement-mediated vessel destruction, while leaving the other arm, interferon-driven inflammation and vessel remodeling, largely untouched.
A second approach targets the vascular side. Treprostinil, a prostacyclin analog that dilates blood vessels and reduces platelet clumping, showed dramatic results in two patients. One experienced complete resolution of skin lesions and disabling finger pain after starting treprostinil for an associated case of pulmonary hypertension. The second saw her blood in the urine clear, neurological symptoms resolve, and brain MRI findings improve.20PubMed Central. Effective treatment of malignant atrophic papulosis (Köhlmeier-Degos disease) with treprostinil–early experience Treprostinil does not target the immune drivers directly, but by keeping vessels open and reducing clot formation, it may limit the downstream tissue damage.
The emerging consensus among specialists who have treated more than one case is that a combined approach works best: complement inhibition, interferon suppression, and a prostacyclin to maintain vessel patency and reduce platelet activation.21The American Journal of Dermatopathology. The Evolution in the Cutaneous and Gastrointestinal Pathology of Pediatric Kohlmeier–Degos Disease Under Combined Modality Therapy Each component attacks a different piece of the cascade, and no single agent has reliably controlled all aspects of the disease. Even with this multimodal strategy, long-term outcomes remain uncertain, and therapy is adjusted case by case.
Older reports of treatment with anticoagulants, antiplatelet drugs, and immunosuppressants like corticosteroids generally show disappointing results, consistent with the idea that the disease is not primarily a clotting disorder that you can simply thin your way out of.22Acta Dermato-Venereologica. A fatal case of malignant atrophic papulosis (Degos’ disease) in a man with factor V Leinden mutation and lupus anticoagulant
Degos Disease in Children
Although most reported cases occur in young to middle-aged adults, Degos disease can appear in childhood, including infancy. A case report documented disease onset during the first year of life with severe neurological involvement, underscoring that the disease does not spare any age group.23PubMed Central. Case Report: Infant-onset Degos disease with nervous system involvement and a literature review Pediatric cases are vanishingly rare, which makes them even harder to study and treat. Most pediatric management follows the same principles as adult treatment, but the complexity of using complement inhibitors and prostacyclin analogs in a growing child adds another layer of clinical challenge. When Degos disease presents in a child, combined modality therapy has been used, with evolving pathology on serial biopsies guiding dose adjustments.24The American Journal of Dermatopathology. The Evolution in the Cutaneous and Gastrointestinal Pathology of Pediatric Kohlmeier–Degos Disease Under Combined Modality Therapy
Surgical Emergencies and Diagnostic Delays
Because Degos disease is so uncommon, it is routinely missed on the first encounter with surgeons, gastroenterologists, and even dermatologists. One striking case involved a patient who was initially diagnosed with Crohn’s disease and taken to surgery for bowel perforation. The surgeon found over a hundred whitish-yellow plaques across the intestine and dozens of perforations. Two meters of perforated small bowel were removed. Five days after surgery, new perforations appeared, and only then did the team recognize the connection between the intestinal findings and the patient’s skin lesions.25PubMed Central. Degos disease with multiple intestinal perforations: A missed-opportunity case report and literature review
This pattern is unfortunately common. Skin lesions may have been present for months or years before the abdominal emergency, but the connection is not made until after a surgical crisis. Part of the problem is that Degos lesions are small and easily dismissed as trivial. A patient showing up in an emergency room with an acute abdomen is not likely to have their skin carefully examined, and even if the papules are noticed, many clinicians have never heard of the condition. The case report above called it a “missed opportunity” for a reason: earlier recognition of the skin lesions could have prompted surveillance imaging or at least raised the index of suspicion, potentially avoiding the delayed second surgery.
For patients who do reach the operating room with Degos-related perforations, the surgical challenge is formidable. The disease does not limit itself to one or two sites. Multiple perforations, sometimes dozens, can be scattered along the small intestine, and new ones can develop after bowel resection. Surgeons have to balance the urgency of controlling peritonitis against the reality that removing too much bowel carries its own devastating consequences, including short bowel syndrome. There are no surgical guidelines specific to Degos disease; management is improvised on a case-by-case basis, often in consultation with dermatologists and rheumatologists who may be more familiar with the condition’s trajectory.
Living with Extreme Rarity
With fewer than a few hundred patients documented over the seven decades since the disease was first described by French dermatologist Robert Degos in the 1940s, the practical reality of living with this condition is shaped by its obscurity. Many patients see multiple specialists before receiving a diagnosis, and even then, the expertise to manage the disease is concentrated in a handful of academic medical centers. No drug carries a formal regulatory approval for Degos disease, meaning everything prescribed is off-label, which can complicate insurance coverage and access.
The mortality data, while grim, deserves context. Published case reports are heavily biased toward the most severe outcomes, because fatal or dramatic cases are more likely to be written up. The true ratio of benign to malignant disease in the wild is unknown and may be somewhat more favorable than the roughly two-to-one split seen in the literature.26PubMed. Clinical manifestations and treatment outcomes in degos disease: a systematic review Still, the possibility of systemic disease developing decades after initial skin-only presentation means that patients require indefinite monitoring, a psychologically taxing state of sustained uncertainty. Regular clinical follow-up, periodic inflammatory marker checks, and a low threshold for imaging when new symptoms arise form the backbone of surveillance, however imperfect.